Buscar
01/09/2025
Clinical features of children with MOG-IgG who fulfill criteria of multiple sclerosis and overlapping disorders
Perez, EGF, Olivé, G, Chen, LW, Paredes-Carmona, F, Nuñez-Enamorado, N, Duran, SB, Mendibe, MD, Visa-Reñe, N, Vasquez-Lopez, M, Felipe-Rucián, A, Romeu, G, Martinez, E, Blanco, Y, Sepulveda, M, Saiz, A, Dalmau, J, Armangue, T. Clinical features of children with MOG-IgG who fulfill criteria of multiple sclerosis and overlapping disorders. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/09/2025
Tocilizumab Did Not Increase the Risk of Severe ICANS in 600 patients treated with CD19 CAR-T Therapy
Cabrera-Maqueda, JM, Perez, EGF, Smith, CS, Chamorro, FJH, García, MA, Velilla, G, Gil-Perotin, SG, Martin-Aguilar, L, Velasco, R, Castillo-Triviño, T, Garcia, JLC, García, PC, García, CI, Cacabelos, PP, González-Suárez, I, Cladera, MM, de Larraya, JGP, Molina, EG, Iglesias, GT, Gallego, MD, Alcántara, LA, Guerra-Fernández, V, Alba, MT, Planagumà, J, Martinez-Cibrian, N, Martínez, E, Blanco, Y. Tocilizumab Did Not Increase the Risk of Severe ICANS in 600 patients treated with CD19 CAR-T Therapy. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/09/2025
NfL and GFAP treatment-response serum biomarkers are influenced by elapsed time from MS onset to ocrelizumab initiation
Velasco, JIF, Jorge, FR, Monreal, E, Gracia, J, Díaz, EF, Meca-Lallana, V, Villarrubia, N, de la Maza, SS, Cortegana, EMP, Quiroga-Varela, A, Ramio-Torrentá, L, Martínez-Yélamos, S, Vila, LB, Real, AML, Romero, AR, Canelo, LB, Nicolas, SD, Eguia, P, Espiño, M, Garcia, JLC, Hernandez, FJB, González, JLV, Meca-Lallana, JE, Martos, PG, Gines, MLM, García-Dominguez, JM, Moreno, I, Sainz, R, Mañe, A, Rodriguez, ABC, Pinedo, FC, Labiano, A, Ayuso, L, Abreu, R, Hernández, MA, Rodríguez, MR, Martín-Aguilar, L, González, AH, Rojas, FJV, Cabredo, LF, Sanchez-Seco, VG, Muñoz, JS, Polo, LF, Castañon, IG, Moreno, SMG, Masjuan, J, Costa-Frossard, L, Guimerans, LMV. NfL and GFAP treatment-response serum biomarkers are influenced by elapsed time from MS onset to ocrelizumab initiation. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/02/2026
The impact of large-scale release of Wolbachia mosquitoes on dengue incidence in Campo Grande, Brazil: an ecological study
Batista, FD, Carcamo, PM, Nelson, E, Neto, ABD, Tsuha, DH, Lahdo, V, dos Santos, VR, Ribeiro, GS, Lopes, RD, Amadeu, P, Blanco, MVFM, da Costa, TR, Chalegre, KDD, Riback, TIS, da Silva, CC, Ranzani, OT, Cummings, DAT, Andrews, JR, Ko, AI, Hitchings, MDT, Anders, KL, Moreira, LA, Gonçalves, CCM, Croda, J. The impact of large-scale release of Wolbachia mosquitoes on dengue incidence in Campo Grande, Brazil: an ecological study. Lancet Regional Health-Americas. 2026; 54DOI:10.1016/j.lana.2025.101327. PMID:41438239. IF:(Q/D).
01/01/2026
Effectiveness of theTAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: atest-negative, case-control study
Ranzani, OT, Neto, FL, Mareto, LK, Brumatti, TS, Oliveira, RDD, Silva, PVD, Santos, ERD, Agostini, TLD, Paula, RACD, Dean, NE, Ko, A, Cummings, DAT, Andrews, JR, Hitchings, MDT, Croda, J. Effectiveness of theTAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: atest-negative, case-control study. LANCET INFECTIOUS DISEASES. 2026; 26(1)DOI:10.1016/S1473-3099(25)00382-2. PMID:40845862. IF:31.000(Q1/1D).
16/12/2025
Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score
Ranzani, OT, Singer, M, Salluh, JIF, Shankar-Hari, M, Pilcher, D, Berger-Estilita, J, Coopersmith, CM, Juffermans, NP, Laffey, J, Reinikainen, M, Neto, AS, Tavares, M, Timsit, JF, Lopez, MDA, Arulkumaran, N, Aryal, D, Azoulay, E, Celi, LA, Chaudhuri, D, De Lange, D, De Waele, J, Dos Santos, CC, Du, B, Einav, S, Engelbrecht, T, Fazla, F, Ferrer, R, Finazzi, S, Fujii, T, Gershengorn, HB, Greene, JD, Haniffa, R, Hao, SC, Hasan, MS, Hollenberg, S, Ippolito, M, Jung, C, Kirov, M, Kobari, S, Lakbar, I, Lipman, J, Liu, V, Liu, XL, Lobo, SM, Magatti, D, Martin, GS, Metnitz, B, Metnitz, P, Myatra, SN, Oczkowski, S, Paiva, JA, Paruk, F, Pekkarinen, PT, Piquilloud, L, Pölkki, A, Prescott, HC, Blaser, AR, Rezende, E, Robba, C, Rochwerg, B, Ruckly, S, Samei, R, Schenck, EJ, Secombe, P, Sendagire, C, Siaw-Frimpong, M, Simpkin, AJ, Soares, M, Summers, C, Szczeklik, W, Takala, J, Tanaka, S, Tricella, G, Vincent, JL, Wendon, J, Zampieri, FG, Rhodes, A, Moreno, R. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2025; 334(23)DOI:10.1001/jama.2025.20516. PMID:41159833. IF:55.000(Q1/1D).